Skip to main content
Top
Published in: Journal of Gastroenterology 5/2019

01-05-2019 | Original Article—Liver, Pancreas, and Biliary Tract

Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer

Authors: Daisuke Hashimoto, Kota Arima, Shigeki Nakagawa, Yuji Negoro, Toshihiko Hirata, Masahiko Hirota, Masafumi Inomata, Kengo Fukuzawa, Takefumi Ohga, Hiroshi Saeki, Eiji Oki, Yo-ichi Yamashita, Akira Chikamoto, Hideo Baba, Yoshihiko Maehara

Published in: Journal of Gastroenterology | Issue 5/2019

Login to get access

Abstract

Background

After initial pancreatic resection, local recurrence of pancreatic cancer (PC) or new primary PC can develop in the remnant. There are limited data available regarding this so-called remnant PC. The aim of this retrospective study was to clarify the clinical features and establish a treatment strategy for remnant PC.

Methods

A multicenter retrospective study with the Kyushu Study Group of Clinical Cancer was carried out. Clinical data from 50 patients who developed remnant PC were analyzed. RAS mutation analysis of the initial tumor and of remnant PC was performed in 17 cases.

Results

The initial pancreatic resections were performed for 37 invasive ductal carcinomas, and for 13 other tumors. Thirty-seven patients underwent a second pancreatectomy for remnant PC (resected group), while thirteen patients were not operated (unresected group). The median overall survival times were 42.2 months in the resected group and 12.3 months in the unresected group (HR 0.374; 95% CI 0.17–0.83). In RAS mutation analysis, 14 cases had at least 1 missense variant of KRAS, HRAS, or NRAS in the initial pancreatic tumor and/or remnant PC. The same missense variants between the initial tumor and remnant PC were discovered only in KRAS of one patient, and in HRAS of one patient. No case had completely consistent missense variants between the initial tumor and remnant PC.

Conclusions

This study found that repeated pancreatectomy for remnant PC can prolong patient survival, and RAS mutation analysis indicated that many remnant PCs are developed from metachronous multifocal origins.
Appendix
Available only for authorised users
Literature
1.
go back to reference Miyata H, Gotoh M, Hirai I, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259:773–80.CrossRefPubMed Miyata H, Gotoh M, Hirai I, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259:773–80.CrossRefPubMed
2.
go back to reference Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMed
3.
go back to reference Otsubo T, Kobayashi S, Sano K, et al. Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J Hepatobiliary Pancreat Sci. 2017;24:252–61.CrossRefPubMed Otsubo T, Kobayashi S, Sano K, et al. Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J Hepatobiliary Pancreat Sci. 2017;24:252–61.CrossRefPubMed
4.
go back to reference Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99–132.PubMed Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9:99–132.PubMed
5.
go back to reference Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005;22:321–8.CrossRefPubMed Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005;22:321–8.CrossRefPubMed
6.
go back to reference Smeenk HG, Tran TC, Erdmann J, et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.CrossRefPubMed Smeenk HG, Tran TC, Erdmann J, et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.CrossRefPubMed
8.
go back to reference Hashimoto D, Chikamoto A, Masuda T, et al. Pancreatic cancer arising from the remnant pancreas: is it a local recurrence or new primary lesion? Pancreas. 2017;46:1083–90.CrossRefPubMed Hashimoto D, Chikamoto A, Masuda T, et al. Pancreatic cancer arising from the remnant pancreas: is it a local recurrence or new primary lesion? Pancreas. 2017;46:1083–90.CrossRefPubMed
9.
go back to reference Hashimoto D, Chikamoto A, Ohmuraya M, et al. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Surg Today. 2014;44:1313–20.CrossRefPubMed Hashimoto D, Chikamoto A, Ohmuraya M, et al. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Surg Today. 2014;44:1313–20.CrossRefPubMed
10.
go back to reference Müller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246:966–74 (discussion#).CrossRefPubMed Müller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246:966–74 (discussion#).CrossRefPubMed
11.
go back to reference Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696–704.CrossRefPubMed Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696–704.CrossRefPubMed
12.
go back to reference Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964–72.CrossRefPubMed Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964–72.CrossRefPubMed
13.
go back to reference Miyazaki M, Yoshitomi H, Shimizu H, et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery. 2014;155:58–66.CrossRefPubMed Miyazaki M, Yoshitomi H, Shimizu H, et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery. 2014;155:58–66.CrossRefPubMed
14.
go back to reference Shima Y, Okabayashi T, Kozuki A, et al. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg. 2015;400:973–8.CrossRefPubMed Shima Y, Okabayashi T, Kozuki A, et al. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg. 2015;400:973–8.CrossRefPubMed
15.
go back to reference Nakagawa M, Choi YY, An JY, et al. Staging for remnant gastric cancer: the metastatic lymph node ratio vs the UICC 7th edition system. Ann Surg Oncol. 2016;23:4322–31.CrossRefPubMed Nakagawa M, Choi YY, An JY, et al. Staging for remnant gastric cancer: the metastatic lymph node ratio vs the UICC 7th edition system. Ann Surg Oncol. 2016;23:4322–31.CrossRefPubMed
16.
go back to reference Qi X, Zhao Y, Li H, et al. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget. 2016;7:34703–51.PubMedPubMedCentral Qi X, Zhao Y, Li H, et al. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget. 2016;7:34703–51.PubMedPubMedCentral
17.
go back to reference Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.CrossRefPubMedPubMedCentral Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.CrossRefPubMedPubMedCentral
18.
go back to reference Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78:1194–9.CrossRefPubMed Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78:1194–9.CrossRefPubMed
19.
go back to reference Miura F, Takada T, Amano H, et al. Repeated pancreatectomy after pancreatoduodenectomy. J Gastrointest Surg. 2007;11:179–86.CrossRefPubMed Miura F, Takada T, Amano H, et al. Repeated pancreatectomy after pancreatoduodenectomy. J Gastrointest Surg. 2007;11:179–86.CrossRefPubMed
20.
go back to reference Ishida J, Toyama H, Matsumoto I, et al. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: high cumulative incidence rates at 5 years after pancreatectomy. Pancreatology. 2016;16:615–20.CrossRefPubMed Ishida J, Toyama H, Matsumoto I, et al. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: high cumulative incidence rates at 5 years after pancreatectomy. Pancreatology. 2016;16:615–20.CrossRefPubMed
21.
go back to reference Lavu H, Nowcid LJ, Klinge MJ, et al. Reoperative completion pancreatectomy for suspected malignant disease of the pancreas. J Surg Res. 2011;170:89–95.CrossRefPubMed Lavu H, Nowcid LJ, Klinge MJ, et al. Reoperative completion pancreatectomy for suspected malignant disease of the pancreas. J Surg Res. 2011;170:89–95.CrossRefPubMed
22.
go back to reference Hashimoto D, Arima K, Yokoyama N, et al. Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma. Pancreas. 2016;45:1111–4.CrossRefPubMed Hashimoto D, Arima K, Yokoyama N, et al. Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma. Pancreas. 2016;45:1111–4.CrossRefPubMed
23.
go back to reference Yamada S, Kobayashi A, Nakamori S, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery. 2018;164:1049–56.CrossRefPubMed Yamada S, Kobayashi A, Nakamori S, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery. 2018;164:1049–56.CrossRefPubMed
24.
go back to reference Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.CrossRefPubMed Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.CrossRefPubMed
25.
go back to reference Cancer IUA: TNM Classification of Malignant Tumours. 7th ed. New York: Wiley-Blackwell; 2009. Cancer IUA: TNM Classification of Malignant Tumours. 7th ed. New York: Wiley-Blackwell; 2009.
26.
go back to reference Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefPubMed Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefPubMed
27.
go back to reference Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMed Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMed
28.
go back to reference Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.CrossRefPubMedPubMedCentral Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.CrossRefPubMedPubMedCentral
29.
go back to reference Yamaguchi K, Okusaka T, Shimizu K, et al. Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society: a synopsis. Pancreas. 2017;46:595–604.CrossRefPubMed Yamaguchi K, Okusaka T, Shimizu K, et al. Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society: a synopsis. Pancreas. 2017;46:595–604.CrossRefPubMed
30.
go back to reference Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
31.
go back to reference Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
32.
go back to reference Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–76.PubMedPubMedCentral Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067–76.PubMedPubMedCentral
33.
go back to reference Matsuda Y, Furukawa T, Yachida S, et al. The prevalence and Clinicopathological characteristics of high-grade pancreatic intraepithelial neoplasia: Autopsy Study evaluating the entire pancreatic parenchyma. Pancreas. 2017;46:658–64.CrossRefPubMed Matsuda Y, Furukawa T, Yachida S, et al. The prevalence and Clinicopathological characteristics of high-grade pancreatic intraepithelial neoplasia: Autopsy Study evaluating the entire pancreatic parenchyma. Pancreas. 2017;46:658–64.CrossRefPubMed
34.
go back to reference Tempero M, Malafa M, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRefPubMed Tempero M, Malafa M, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–61.CrossRefPubMed
35.
go back to reference Heinrich S, Pestalozzi B, Lesurtel M, et al. Adjuvant gemcitabine versus neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346.CrossRefPubMedPubMedCentral Heinrich S, Pestalozzi B, Lesurtel M, et al. Adjuvant gemcitabine versus neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346.CrossRefPubMedPubMedCentral
36.
go back to reference Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg. 2005;9:1059–66 (discussion#).CrossRefPubMed Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg. 2005;9:1059–66 (discussion#).CrossRefPubMed
Metadata
Title
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer
Authors
Daisuke Hashimoto
Kota Arima
Shigeki Nakagawa
Yuji Negoro
Toshihiko Hirata
Masahiko Hirota
Masafumi Inomata
Kengo Fukuzawa
Takefumi Ohga
Hiroshi Saeki
Eiji Oki
Yo-ichi Yamashita
Akira Chikamoto
Hideo Baba
Yoshihiko Maehara
Publication date
01-05-2019
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2019
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-018-01535-9

Other articles of this Issue 5/2019

Journal of Gastroenterology 5/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.